EMEA-001214-PIP02-17

Key facts

Active substance
benralizumab
Therapeutic area
Oto-rhino-laryngology
Decision number
P/0288/2017
PIP number
EMEA-001214-PIP02-17
Pharmaceutical form(s)
Solution for injection in pre-filled syringe
Condition(s) / indication(s)
Treatment of nasal polyposis
Route(s) of administration
Subcutaneous use
Contact for public enquiries
AstraZeneca AB (Sweden)

Tel. +46 8 5532791
E-mail: paediatrics@astrazeneca.com

Decision type
W: decision granting a waiver in all age groups for all conditions or indications

Decision

How useful was this page?

Add your rating